Literature DB >> 16372170

Sclerotherapy for venous malformations using a "negative subtraction" technique.

Ronit Agid1, Ram Burvin, John M Gomori.   

Abstract

We describe a technique of injecting alcohol into venous malformations (VM) under slow digital subtraction angiography (DSA) which eliminates the need to pre-mix the alcohol with a contrast agent. The technique presented here is especially helpful when Metrizamide is not available or not permitted for use. It offers an elegant way to visualize, in real time, the alcohol injected into the VM, while preserving its high concentration and potency as a sclerosing agent.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16372170     DOI: 10.1007/s00234-005-0019-2

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  4 in total

1.  [Percutaneous sclerotherapy for the treatment of soft-tissue venous malformations: a retrospective study of 68 patients].

Authors:  L Blum; S Gallas; J P Cottier; C B Sonier Vinikoff; G Lorette; D Herbreteau
Journal:  J Radiol       Date:  2004-02

2.  Soft-tissue venous malformations in children: percutaneous sclerotherapy with Ethibloc.

Authors:  J M Dubois; G H Sebag; Y De Prost; D Teillac; B Chretien; F O Brunelle
Journal:  Radiology       Date:  1991-07       Impact factor: 11.105

3.  Soft-tissue venous malformations in adult patients: imaging and therapeutic issues.

Authors:  J Dubois; G Soulez; V L Oliva; M J Berthiaume; C Lapierre; E Therasse
Journal:  Radiographics       Date:  2001 Nov-Dec       Impact factor: 5.333

4.  Sclerotherapy for venous malformations.

Authors:  A A de Lorimier
Journal:  J Pediatr Surg       Date:  1995-02       Impact factor: 2.545

  4 in total
  1 in total

1.  Percutaneous sclerotherapy for facial venous malformations: subjective clinical and objective MR imaging follow-up results.

Authors:  J Spence; T Krings; K G terBrugge; L B da Costa; R Agid
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-31       Impact factor: 3.825

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.